80 results
Page 3 of 4
8-K
EX-99.1
sj6482722o07t18rdv7
19 May 21
Regulation FD Disclosure
5:00pm
8-K
EX-99.1
x6lcvzpzc73do1 x4d9
7 May 21
Business Highlights and 2021 Anticipated Milestones
7:00am
S-3ASR
4640x lmz6iyb
2 Apr 21
Automatic shelf registration
4:59pm
8-K
EX-99.1
0jxgah uj5pld
18 Mar 21
Sutro Biopharma Reports Full Year 2020 Financial Results
7:00am
424B5
f1bbrh67 6989gq
9 Dec 20
Prospectus supplement for primary offering
4:02pm
424B5
p0vjwdif9
7 Dec 20
Prospectus supplement for primary offering
4:10pm
8-K
EX-99.1
o18d9zq
7 Dec 20
Regulation FD Disclosure
3:45pm
8-K
EX-99.1
kdpqiw1
4 Dec 20
Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer
12:00am
8-K
EX-99.2
1z7dexzon7liaas3
4 Dec 20
Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer
12:00am
8-K
EX-99.1
rwco1wvxj8fa 819zh
5 Nov 20
Sutro Biopharma Reports Third Quarter 2020 Financial Results
7:05am
8-K
EX-99.1
ktmlgom 9ih8
9 Sep 20
Other Events
5:23pm
8-K
EX-99.1
ixwppuzpnve6hu9rn
6 Aug 20
Sutro Biopharma Reports Second Quarter 2020 Financial Results
7:03am
8-K
EX-99.1
0v5t8i28n4f7e3ut
15 Jun 20
Regulation FD Disclosure
7:21am
424B5
br7v38 irpxgvgooojo
12 May 20
Prospectus supplement for primary offering
5:02pm
8-K
EX-99.1
mj085kvxy61i
11 May 20
Sutro Biopharma Reports First Quarter 2020 Financial Results
4:27pm
424B5
7pe30q5
11 May 20
Prospectus supplement for primary offering
4:12pm